Francesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-04-14 12:13:462021-04-14 12:13:46Change in Management
Swiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
Change in Management
AppointmentsFrancesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.
BioVersys gets €20m EIB loan to develop novel antibiotics
Latest NewsSwiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
Latest NewsC4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.